Omeros (NASDAQ:OMER) Given Hold Rating at Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating restated by equities research analysts at Needham & Company LLC in a research report issued on Wednesday, AnalystRatings.com reports.

Several other research firms have also weighed in on OMER. Wedbush restated a “hold” rating and set a $18.00 target price on shares of Omeros in a report on Friday, November 15th. Maxim Group set a $32.00 price target on Omeros and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research lowered Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, November 16th. ValuEngine cut Omeros from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price (down previously from $35.00) on shares of Omeros in a research report on Monday. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $25.40.

NASDAQ OMER traded up $0.85 during mid-day trading on Wednesday, hitting $15.22. The company’s stock had a trading volume of 75,911 shares, compared to its average volume of 496,082. Omeros has a 52-week low of $10.30 and a 52-week high of $20.92. The stock’s fifty day simple moving average is $14.79 and its two-hundred day simple moving average is $16.48. The firm has a market capitalization of $714.91 million, a P/E ratio of -6.83 and a beta of 2.65.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.08. The business had revenue of $29.86 million for the quarter, compared to analysts’ expectations of $27.19 million. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. Omeros’s quarterly revenue was up 547.7% compared to the same quarter last year. As a group, research analysts anticipate that Omeros will post -1.13 earnings per share for the current year.

In other news, Director Thomas J. Cable sold 5,000 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $15.12, for a total value of $75,600.00. Following the completion of the transaction, the director now directly owns 35,067 shares in the company, valued at $530,213.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in OMER. Nuveen Asset Management LLC acquired a new stake in shares of Omeros during the second quarter worth approximately $3,221,000. Chicago Equity Partners LLC acquired a new stake in Omeros in the second quarter valued at $1,094,000. Stifel Financial Corp boosted its stake in Omeros by 9.4% during the 3rd quarter. Stifel Financial Corp now owns 740,959 shares of the biopharmaceutical company’s stock valued at $12,092,000 after acquiring an additional 63,891 shares during the last quarter. Ingalls & Snyder LLC grew its holdings in Omeros by 1.2% during the 3rd quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock worth $82,038,000 after acquiring an additional 58,198 shares in the last quarter. Finally, Virtus ETF Advisers LLC acquired a new position in Omeros during the 2nd quarter worth $784,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: What is the definition of market timing?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.